Filing summary
Identity and period: The supplied filing is Trail One, Inc.’s unaudited Form 10-Q for the quarter ended December 31, 2013, not a filing identified as Citius Pharmaceuticals, Inc. The company reports a September 30 fiscal year-end.
Business context and results
Trail One describes itself as a development-stage business formed to market customized decorative automobile license-plate tags; it had not generated sales. It was also negotiating, on a non-binding basis, a possible reverse merger with another business.
- Revenue: $0 for the quarter, unchanged from the prior-year quarter. Gross margin is not meaningful because there were no sales.
- Expenses and loss: Operating expenses were $298 versus $636; interest expense was $67 versus $784. Net loss was $365 versus $1,420. Basic and diluted loss per share were each reported as $0.00, rounded.
- Cash flow: Net cash used in operating activities was $17,524, offset by $17,524 in financing cash inflows; ending cash was $0. Investing cash flow was $0.
- Balance sheet at December 31, 2013: Total assets were $5,950, all reported as prepaid expenses; current liabilities were $20,999, including $20,723 of notes payable and $78 of accrued interest. Working capital and stockholders’ equity were each negative $15,049. Accumulated deficit was $95,581.
- Debt and financing: The $20,723 notes payable were loans from Highline Research Advisors LLC, bearing 5% interest and due on demand. The filing says additional equity or debt financing is needed.
Changes, outlook, and risks
- Compared with the quarter ended December 31, 2012, operating expenses, interest expense, and net loss decreased; revenue remained zero. The balance sheet shows notes payable rising from $3,200 at September 30, 2013 to $20,723 at December 31, 2013.
- Management said the company lacked sufficient cash for the next 12 months, did not expect product revenue to cover expenses, and was seeking financing. It cited an approximate monthly burn rate of $122, while reporting quarterly operating cash use of $17,524.
- The filing states that recurring losses, no revenue, zero cash, and a working-capital deficit raise substantial doubt about the company’s ability to continue as a going concern. No assurance was given that financing or the proposed reverse merger would be completed.
- A reverse merger could involve issuing shares that change control and assuming the acquired business’s obligations, including debt. Equity financing could dilute existing holders; debt could impose senior claims and operating restrictions.
- Management concluded disclosure controls were ineffective, citing lack of an independent board or audit committee, inadequate segregation of duties, and reliance on a financial consultant for reporting.
- The filing reports no material pending legal proceedings, no defaults upon senior securities, and no off-balance-sheet arrangements material to investors.
Most important facts to verify
- Confirm the issuer: this document names Trail One, Inc., not Citius Pharmaceuticals, Inc.
- Verify the reported $17,524 of quarterly operating cash use against the financial statements and the stated $122 monthly burn rate.
- Confirm the amount, terms, due-on-demand status, and related-party or other connections, if any, of the Highline notes.
- Check subsequent filings for financing, changes in liquidity, and the status or terms of the proposed reverse merger.
- Review remediation of the disclosed ineffective controls and any resulting changes to financial reporting.